Parkinson's Flashcards
Parkison’s
S/S
- Bradykinesia/akinesia
- Tremor (pill-rolling)
- Rigidity (cogwheel)
- Impairment of postural balance
*mask face, shuffling gait, autonomic, weight-loss, anorexia, depression
Parkinson’s
Pathology
- Dop neuron degeneration
- > 65 years
- more cells lost - worse disease
Parkinson’s
CNS pathway
Nigrostriatal projection DEGENERATE
*substantia nigra –> Striatum
Parkison’s
problem with replacing dopamine
Mesocorticolimbic = Ventral tegmental –> nucleus accumbens
Too much = psychosis
Parkison’s
Smoking
Neuroprotective
GABA pathway
Nigrostriatal = Dopamine (D2) inhibit GABA DIES
Cholinergic = Ach (M) excitatory
MPTP
Goes to MPP+, selectively destroys Substantia Nigra neurons
Selegiline
Stops development of parkinson in monkeys
Suspected source of parkinson’s?
Pesticides, chemical in (country?)
Pharm target =
Imbalance between striatal cholinergic + dopaminergic activity
Pharm strategies
- Dopa replacement
- Enzyme inhibition
- MAO-B inhibition
- Up Dopa release, block reuptake
- stim dopa receptor
- anticholinergic (m)
Dopamine replacement
- L-DOPA levodopa (dopa precursor)
- Use Aromatic amino acid transporter
- 95% lost in periphery
Dopa can’t cross
Peripheral Dopa Toxicity
- Nausea (CTZ)
- Cardiac palpitations + arrythmia (b-agonist)
- Postural HypoTN (vascular DA receptor)
DOPA
CNA toxicity
- Psychotic (accumbens, limbic system)
- Dyskinesias (striatum)
- On-off phenomenon (variable CNS metabolism)
- -Off = dystonia
- -ON = good but dyskenesia
Control on -off phenomenon
Enzyme inhibition =
COMT
MAO-B
L-DOPA
Contraindications
- Psychosis
- Melanoma
- Narrow angle glaucoma
look at slides for info
L-Dopa
Rx interaction
- Non-selective MAO inhibitors - gets MAO-A (selective for MAO-B ok)
- Vitamin B6 (up peripheral metab=More S.E.)
- anti-psycs (work against each other)
B6 effect on L-DOPA
Ups levodopa conversion to DA peripheral
L- DOPA
Clinical problems
- Tolerance
- Gradually degenerating CNS nerves = can’t convert L-Dopa
- Limited effectiveness (1/3)